BiOasis announced siRNA breakthrough; Mystic Pharma receives patent for powdered formulation;

> Mystic Pharma received a patent Notice of Allowance for their powdered formulations of drugs patients can self-administer. Release

> A new cancer therapy research partnership has been arranged between Molecular Targeting Technologies (MTTI) and Taiwan's National Health Research Institutes (NHRI). Release

> Florida Agricultural and Mechanical University received a $100,000 grant from the National Science Foundation to use toward a pilot program launch with the National High Magnetic Field Laboratory. If the program is a success, it can lead to additional millions in funding. Release

> Up and coming biopharma, biOasis announced that it discovered a carrier peptide, Transcendpep, that can cross the blood-brain barrier, effectively delivering siRNA's to the brain. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.